Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Citi
Teva
Julphar
Healthtrust
Chubb

Generated: April 18, 2019

DrugPatentWatch Database Preview

Cefdinir - Generic Drug Details

« Back to Dashboard

What are the generic sources for cefdinir and what is the scope of cefdinir patent protection?

Cefdinir is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Lupin, Orchid Hlthcare, Sandoz, Teva Pharms, and Abbvie, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for cefdinir. Thirty-two suppliers are listed for this compound.

Pharmacology for cefdinir
Synonyms for cefdinir
(-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime
(6r-(6-alpha,7-beta(z)))-)(hydroxyiminoacetyl)amino)-3-ethenyl-8-oxo
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2E)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-hydroxyimino-1-oxoethyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-hydroxyimino-acetyl]amino]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-azanyl-1,3-thiazol-4-yl)-2-hydroxyimino-ethanoyl]amino]-3-ethenyl-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(7R)-3-Vinyl-7-[[(2-amino-4-thiazolyl)[(E)-hydroxyimino]acetyl]amino]cepham-3-ene-4-carboxylic acid
(E)-Cefdinir
(z)-7beta-[2-(2-amino-4-thiazolyl)-2-(hydroxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid
178601-88-2
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl) (hydroxyimino)acetyl)amino)-3-ethenyl-8-oxo-, (6R-(6alpha,7beta(Z)))-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyiminoacetyl)amino)-3-ethenyl-8-oxo-, (6R-(6-alpha,7-beta(Z)))-
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, (6R,7R)-
61G2M33IGF
7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid
7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
7beta-[(Z)-2-(2-AMINO-4-THIAZOLYL)-2-HYDROXYIMINO ACETAMIDO]-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID
7beta-[2-(2-amino-4-thiazolyl)-2-(z-hydroxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid
8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid
832C405
91832-40-5
A844075
AB01274720_02
AB01274720_03
AB01274720-01
AB1009352
ABP000637
AC-1246
AC1O4R30
AC1OCD3C
AK162391
AKOS015951262
AKOS015964069
AKOS032960348
AN-15138
API0001887
AS-14294
AS-35316
BC213681
BCP9000503
BCPP000293
BIDD:GT0827
BMY 28488
BMY-28488
bmy28488
BRD-K15766189-001-05-6
BRD-K52735702-001-01-2
BRD-K52735702-001-02-0
BSPBio_002735
C08110
C14H13N5O5S2
CCG-39455
Cefdinir (JP17/USAN/INN)
Cefdinir (Omnicef)
Cefdinir [USAN:INN]
Cefdinir [USAN:USP:INN:BAN]
Cefdinir, Antibiotic for Culture Media Use Only
Cefdinir, E-
Cefdinir(Omnicef)
Cefdinir(Omnicef)/
Cefdinirum
Cefdinirum [INN-Latin]
Cefdinyl
Cefdirnir
Ceftinex
Cefzon
Cefzon (TN)
CFDN
CHEBI:3485
CHEBI:94470
CHEMBL927
CI 983
CI-983
CI0FAO63WC
cid_6915944
CPD000469224
CS-1925
D00917
DB00535
DTXSID8046084
E-Cefdinir
FK 482
FK-482
FR-80482
HMS1922L19
HMS2093K20
HMS3715F07
HY-B0136
K673
LS-149988
MLS001304703
MLS001424233
MLS006010415
MolPort-002-885-812
MolPort-003-845-683
MolPort-044-724-244
NCGC00178499-01
NSC-758926
NSC758926
Omnicef
Omnicef (TN)
PD 134393
PD-134393
Pharmakon1600-01505208
PubChem13658
RTXOFQZKPXMALH-GHXIOONMSA-N
s1605
SAM001246818
SBI-0206739.P001
SC-17007
SCHEMBL36995
SCHEMBL36996
SCHEMBL5919457
SPECTRUM1505208
Spectrum5_001560
SR-05000001991
SR-05000001991-1
SR-05000001991-2
ST24046294
SW197768-3
UNII-61G2M33IGF
UNII-CI0FAO63WC
X-2542
ZINC13119676
ZINC3927198

US Patents and Regulatory Information for cefdinir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz CEFDINIR cefdinir CAPSULE;ORAL 065330-001 Apr 6, 2007 AB RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin CEFDINIR cefdinir FOR SUSPENSION;ORAL 065259-001 May 31, 2006 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie OMNICEF cefdinir CAPSULE;ORAL 050739-001 Dec 4, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aurobindo Pharma CEFDINIR cefdinir FOR SUSPENSION;ORAL 065473-002 Dec 14, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-002 Jul 29, 2004 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-001 Dec 4, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for cefdinir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-002 Jul 29, 2004 ➤ Sign Up ➤ Sign Up
Abbvie OMNICEF cefdinir CAPSULE;ORAL 050739-001 Dec 4, 1997 ➤ Sign Up ➤ Sign Up
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-001 Dec 4, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Colorcon
Argus Health
Covington
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.